Drug Profile


Alternative Names: Elitek; Fasturtec; Rasuritek; SR 29142; Urate oxidase - Sanofi-Aventis; Urate oxydase; Uricase - Sanofi-Aventis; Uricozyme

Latest Information Update: 14 May 2015

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antigouts; Oxidoreductases
  • Mechanism of Action Oxidoreductase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperuricaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2014 Rasburicase licensed to Emcure Pharmaceuticals in India
  • 17 Oct 2009 Registered for Hyperuricaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top